Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Biopharma company developing personalized medicines for cardiovascular disease patients, focused on functional cures for heart failure.
Kardigan is a biopharmaceutical company based in South San Francisco, California, and Princeton, New Jersey, focused on developing personalized medicines for cardiovascular diseases, emphasizing functional cures over symptom management. The company has secured substantial funding, including a $300 million Series A in 2024 and a $254 million Series B in 2025, with investments from firms like Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. Kardigan builds its portfolio through a discovery platform, in-licensing, and acquisitions, targeting unmet needs in conditions such as cardiomyopathies leading to heart failure. By early 2025, the organization had expanded to approximately 60 employees. Founded in 2023 by Tassos Gianakakos, Jay Edelberg, and Bob McDowell, Kardigan advances a late-stage pipeline of cardiovascular therapies. Its business model centers on venture capital-funded biopharma company advancing a late-stage pipeline of cardiovascular therapies.
Kardigan has raised $550.0M across 2 funding rounds.
Kardigan has raised $550.0M in total across 2 funding rounds.
Kardigan is a patient-driven heart health biopharmaceutical company modernizing cardiovascular drug development to deliver personalized medicines that advance patients beyond symptom management toward functional cures.[1][2][4] Founded in 2023 and based in South San Francisco, California, and Princeton, New Jersey, it develops a portfolio of late-stage candidates targeting underlying disease drivers like genetic dilated cardiomyopathy (DCM), calcific aortic valve stenosis (CAVS), and acute severe hypertension (ASH).[2][3][4][5] The company has raised over $554 million, including a $300 million Series A from Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage, followed by a $254 million Series B with additional investors like T. Rowe Price Investment Management.[1][3] With 56 employees and led by CEO Tassos Gianakakos, Kardigan leverages a cardiac intelligence platform integrating AI, real-world data, and proprietary tools to match treatments to patient responders, accelerating efficiency across programs.[1][4]
Kardigan serves patients with cardiovascular diseases—the leading global cause of death—by building a fully integrated R&D engine through discovery, in-licensing, and acquisitions.[1][3] Its growth momentum includes simultaneous advancement of three lead late-stage programs, integration of Prolaio’s AI platform for trial optimization, and active hiring in South San Francisco to expand its industry-leading team of former MyoKardia executives.[2][3][4]
Kardigan was founded in 2023 by Tassos Gianakakos, who serves as co-founder, CEO, and chair, alongside fellow former MyoKardia executives with proven track records in building transformative cardiovascular businesses.[1][2] The idea emerged from a vision to rethink drug development for heart health, addressing the field's stagnation in symptom management by targeting root causes with personalized approaches.[1][4] Launching with a $300 million Series A, Kardigan quickly curated a late-stage portfolio via strategic in-licensing and its discovery platform, marking early traction.[1][3]
Pivotal moments include the 2025 Series B raise of $254 million to propel its pipeline, affirming investor confidence in its data-driven model.[3] This capital-efficient build—powered by cardiac intelligence—positions Kardigan to deliver multiple medicines faster than traditional biopharma, humanizing its mission through a patient-first culture.[1][4][6]
Kardigan rides the AI-biotech convergence trend, applying cardiac-specific data platforms to cardiovascular disease—a $1 trillion+ market where innovation has lagged despite it being the top global killer.[1][4][5] Timing is ideal amid rising demand for precision medicine, post-pandemic heart health awareness, and AI tools reducing drug development costs by informing trial design.[3][4] Favorable forces include abundant real-world data, investor appetite for capital-efficient biopharma (evidenced by its rapid funding), and unmet needs in genetic heart conditions.[1][3]
By generating shared clinical insights across programs, Kardigan influences the ecosystem, accelerating cures and setting a model for integrated, data-powered cardio biopharma, potentially inspiring similar platforms in other therapeutic areas.[1][4]
Kardigan is poised to disrupt cardiovascular care by delivering first-in-class therapies from its pipeline, with near-term milestones in advancing DCM, CAVS, and ASH programs toward approval.[3][5] Trends like AI-driven personalization and multi-asset parallelism will shape its path, enabling faster iterations and expansions beyond current indications.[4] Its influence may evolve into a cardio innovation hub, licensing insights or acquiring assets to dominate preventable heart disease.
This positions Kardigan as a high-momentum player modernizing a critical field, fulfilling its launch vision of making cardiovascular disease curable and no longer the world's leading killer.[1][5]
Kardigan has raised $550.0M in total across 2 funding rounds.
Kardigan's investors include ARCH Venture Partners, Venrock, Fidelity Management & Research Company, Sequoia Capital, T. Rowe Price Associates, Doug Giordano.
Kardigan has raised $550.0M across 2 funding rounds. Most recently, it raised $250.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $250M Series B | — | ARCH Venture Partners, Venrock, Fidelity Management & Research Company, Sequoia Capital, T. Rowe Price Associates | Announced |
| Jan 1, 2025 | $300M Series A | ARCH Venture Partners, Doug Giordano, Sequoia Capital | Venrock | Announced |